Compounds > bms-986094
Page last updated: 2024-11-13

bms-986094

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BMS-986094: a prodrug of 2'-C-methylguanosine and antiviral agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46700744
CHEMBL ID1209734
SCHEMBL ID14934186
MeSH IDM000610781

Synonyms (28)

Synonym
CHEMBL1209734
inx-089
inx-189
bms-986094
inx 08189
inx-08189
inx08189
62f4ad749y ,
1234490-83-5
bms 986094
unii-62f4ad749y
2,2-dimethylpropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2-amino-6-methoxy-purin-9-yl)-3,4-dihydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-(1-naphthyloxy)phosphoryl]amino]propanoate
SCHEMBL14934186
DTXSID00154017
neopentyl ((((2r,3r,4r,5r)-5-(2-amino-6-methoxy-9h-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-l-alaninate
mfcd22124897
2,2-dimethylpropyl (2s)-2-[({[(2r,3r,4r,5r)-3,4-dihydroxy-5-(2-imino-6-methoxy-3,9-dihydro-2h-purin-9-yl)-4-methyloxolan-2-yl]methoxy}(naphthalen-1-yloxy)phosphoryl)amino]propanoate
AS-74509
HY-13337
CS-0003198
DB11966
neopentyl [[[(2r,3r,4r,5r)-5-(2-amino-6-methoxy-9h-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl]methoxy](naphthalen-1-yloxy)phosphoryl]-l-alaninate
BCP34230
2,2-dimethylpropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
Q27263478
AKOS037647691
bms986094
AKOS040748584

Research Excerpts

Toxicity

BMS-986094, a 2'-C-methylguanosine prodrug that was in development for treatment of chronic hepatitis C infection was withdrawn from Phase 2 clinical trials because of unexpected cardiac and renal adverse events. Motion imaging analysis revealed the difference in cardiotoxicity between the cardiotoxic BMS- 986094 and the less toxic sofosbuvir.

ExcerptReferenceRelevance
" To better understand the mechanism for adverse events, clinically relevant HCV NI were characterized in biochemical and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration."( Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.
Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H, 2016)		0.43
"BMS-986094, a 2'-C-methylguanosine prodrug that was in development for treatment of chronic hepatitis C infection was withdrawn from Phase 2 clinical trials because of unexpected cardiac and renal adverse events."( From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor.
Bounous, D; Clark, S; Davies, M; Gill, M; Graziano, M; Hennan, J; Horn, K; Janovitz, E; Megill, JR; Sanderson, T; White, R, 2017)		2.12
" Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis."( Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs.
Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G, 2017)		0.46
" Motion imaging analysis revealed the difference in cardiotoxicity between the cardiotoxic BMS-986094 and the less toxic sofosbuvir in hiPSC-CMs, with a minimum of 4 days of treatment."( Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes.
Hayashi, S; Kanda, Y; Ono, A; Satsuka, A; Yanagida, S, 2021)		1.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1293405Cytotoxicity against human HuH7 cells infected with HCV assessed as reduction in cellular rRNA level after 96 hrs by qRT-PCR analysis2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
AID1293403Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
AID1595518Cytotoxicity against human U937 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID690810Clast in Sprague-Dawley rat liver assessed as 2'-C-methyl guanosine triphosphate level at 10 mg/kg, po up to 24 hrs by LC-MS/Ms analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents.
AID1293402Cytotoxicity against human PBMC after 6 days by trypan blue exclusion assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
AID740798Cytotoxicity against human HuH7 cells2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and evaluation against hepatitis C virus of 7-deaza analogues of 2'-C-methyl-6-O-methyl guanosine nucleoside and L-Alanine ester phosphoramidates.
AID621511Antiviral activity against Hepatitis C virus subtype 1b replicon in human HuH7 cells after 48 hrs by subgenomic replicon assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus.
AID494752Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral replication by cell-based replicon assay2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.
AID1853906AUC (0 to infinity) in cynomolgus monkey at 30 mg/kg, po2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2.
AID1203815Antiviral activity against HCV infected in human HuH7 cells assessed as reduction in replicon RNA levels incubated for 5 days by RT-PCR assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID621516Antiviral activity against Hepatitis C virus subtype 1b replicon in by replicon assay in presence of adenosine deaminase inhibitor pentostatin2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus.
AID1203819Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 5 days by Cell-titer 96 aqueous one solution cell proliferation assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1203826Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 50 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID690811Tmax in Sprague-Dawley rat liver assessed as 2'-C-methyl guanosine triphosphate level at 10 mg/kg, po up to 24 hrs by LC-MS/Ms analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents.
AID494753Cytotoxicity against human HuH7 cells2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.
AID1203816Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels incubated for 5 days by RT-PCR assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1853865Antiviral activity against HCV assessed as reduction in viral replication by measuring parent nucleoside compound2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2.
AID1293401Antiviral activity against HCV infected in HuH7 Clone B cells assessed as inhibition of viral replication after 5 days by RT-PCR method2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
AID690809Cmax in Sprague-Dawley rat liver assessed as 2'-C-methyl guanosine triphosphate level at 10 mg/kg, po up to 24 hrs by LC-MS/Ms analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents.
AID740799Antiviral activity against Hepatitis C virus assessed as inhibition of viral replication2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and evaluation against hepatitis C virus of 7-deaza analogues of 2'-C-methyl-6-O-methyl guanosine nucleoside and L-Alanine ester phosphoramidates.
AID1293404Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometry2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
AID494754Permeability across human Caco-2 cells from apical to basolateral side in human Caco2 cell membrane2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.
AID1595515Cytotoxicity against human HepG2 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID1203824Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 1 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1203817Cytotoxicity against human PBMC assessed as reduction in cell viability incubated for 5 days by Cell-titer 96 aqueous one solution cell proliferation assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1203818Cytotoxicity against human CEM cells assessed as reduction in cell viability incubated for 5 days by Cell-titer 96 aqueous one solution cell proliferation assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1595517Cytotoxicity against human HeLa cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID1595514Cytotoxicity against human HuH7 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID1595516Cytotoxicity against human A549 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID1853866Antiviral activity against HCV assessed as reduction in viral replication by measuring monophosphate prodrug metabolite2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2.
AID690812AUC (0 to t) in Sprague-Dawley rat liver assessed as 2'-C-methyl guanosine triphosphate level at 10 mg/kg, po up to 24 hrs by LC-MS/Ms analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents.
AID621512Cytotoxicity against human HuH7 cells2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus.
AID1203828Toxicity in human HepG2 cells assessed as increase in cell death at 10 uM2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1203825Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 10 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID494755Cmax in primary human hepatocytes after 2uM treatment2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.
AID1203823Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1203822Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID1595519Cytotoxicity against human MT4 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
AID1203827Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 100 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's16 (88.89)24.3611
2020's2 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.34 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index6.04 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		2.06102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
triphosphoric acid
triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure		2.1110acyclic phosphorus acid anhydride;
phosphorus oxoacid
phenol
[no description available]		2.4920phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
cytidine
[no description available]		2.1510cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.1510diazine;
pyrazines		Daphnia magna metabolite
deoxycytidine
[no description available]		2.1310pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.1110pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
lamivudine
[no description available]		2.1110monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.5420adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
phosphoramidic acid
phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds		2.0510phosphoric acid derivative
2-aminoadenosine
[no description available]		2.1310purine nucleoside
4'-azidocytidine
4'-azidocytidine: antiviral; structure in first source		2.1510N-glycosyl compound
favipiravir
favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.		2.1510hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
mk 0608
7-deaza-2'-C-methyladenosine: an antiviral agent		2.0810
balapiravir
balapiravir: a prodrug of R1479; structure in first source		2.5420
rg 7128
2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source		2.1310
GS-441524
[no description available]		2.4110aromatic amine;
C-nucleoside;
nitrile;
pyrrolotriazine		anticoronaviral agent;
antiviral agent;
drug metabolite
nitd008
NITD008: inhibits enterovirus 71		2.1510
sofosbuvir
[no description available]		2.2110
sofosbuvir
Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		7.8330isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
guanosine monophosphate
Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.		5.3111guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.1310guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		7.8230guanosines;
purines D-ribonucleoside		fundamental metabolite
inosinic acid
Inosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.		2.1310inosine phosphate;
purine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
idx184
IDX184: prodrug to enhance formation in the liver of the active triphosphate of 2'-methylguanosine, a potent and specific polymerase inhibitor of the hepatitis C virus; structure in first source		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		03.0340
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		110.0340
Chronic Illness
[description not available]		02.3110
Cardiac Toxicity
[description not available]		02.3110
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.3110
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		07.3110
Chronic Hepatitis C
[description not available]		04.2131
Cardiomyopathies, Primary
[description not available]		03.511
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		03.511
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.		04.2131
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.1110